To Observe the CD7-targeted CAR-T Therapy in the Treatment of r/r PTCL

NCT07143929 | Recruiting Phase 1

• 1 other identifier: Anti CD7 CAR-T for r/r PTCL
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 1

Brief Summary

To observe the efficacy and safety of CD7-targeted chimeric antigen receptor T cells in the treatment of refractory or relapsed PTCL.

Conditions

CD7 Positive R/R PTCL

Outcome Measures

Primary Outcomes (1)

• safety: Dose-limiting toxicity

  Observe the incidence rate of DLT events within 28 days after cell infusion

  at least 28 days after the CAR-T cells infusion

Secondary Outcomes (1)

• Efficacy of the anti CD7 CAR-T cells to R/R PTCL

  at least 1 year after the CAR-T cells infusion

Study Arms (1)

anti CD7 CAR-T cells

EXPERIMENTAL

eligible patients will be treated with CD7-targeted CAR-T cells

Drug: CAR-T

Interventions

CAR-T DRUG

autologous CD7-targeted CAR-T cells, single injection

anti CD7 CAR-T cells

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18 years old and\<80 years old；
• According to the clinical practice guidelines for T-cell lymphoma of the National Comprehensive Cancer Network (NCCN) (2022. v2), diagnosis of peripheral T-cell lymphoma；
• Relapse or refractory peripheral T-cell lymphoma, which has not achieved remission or relapsed after receiving ≥ 1 line of systemic treatment in the past；
• Histologically confirmed as CD7 positive；
• According to Lugano2014 standard, enhanced CT before enrollment should indicate at least one evaluable tumor lesion, and PET/CT should show metabolic activity.
• Blood routine neutrophil count ≥ 1.0×109/L during screening; For individuals without bone marrow invasion, platelet count ≥ 75×109/L, Hb≥80g/L; For individuals with bone marrow invasion, platelet count ≥50×109/L, Hb≥60g/L；
• Creatinine clearance rate\>60ml/min (Cockcroft and Gault formula); serum total bilirubin≤1.5 times the upper limit of normal value, and serum ALT and AST ≤ 3 times the upper limit of normal value range;
• left ventricular Ejection fraction (LVEF) ≥ 50%.
• Estimated survival time of over 3 months.
• ECOG: 0-1.
• Subjects or their Legal guardian voluntarily participate in the trial and sign the informed consent form.

You may not qualify if:

• Primary cutaneous T-cell lymphoma, including mycosis fungoides (MF) and Sezary syndrome (SS); T-lymphoblastic leukemia/lymphoma（T-ALL/LBL）；
• Primary central nervous system cell lymphoma, or with active central nervous system invasion；
• If anti-tumor treatment has been received before infusion, and drugs have not been completely eliminated must be excluded;
• Individuals with a history of allergies to any component in cellular products.
• Cardiac function:cardiac dysfunction classified as Class III or IV；Myocardial infarction, cardiac angioplasty or stenting, unstable angina pectoris, or other serious heart disease clinically within 12 months of enrollment；The electrocardiogram indicates that the QT interval is significantly prolonged, and the patient has serious heart disease such as serious arrhythmia in the past.
• Previous history of craniocerebral trauma, Disorders of consciousness, epilepsy, cerebrovascular ischemia, cerebrovascular hemorrhagic disease, etc.
• Uncontrolled severe active infections.
• The subject has a history of other primary cancers, except for the following.
• Subjects with autoimmune diseases requiring treatment or subjects requiring Immunosuppressive drug treatment.
• Individuals with graft versus host disease (GvHD) and/or requiring immunosuppressive therapy.
• Live vaccination within 4 weeks prior to screening.
• The subject has a history of alcoholism, drug abuse, or mental illness.
• Individuals with EBV DNA copy numbers greater than the upper limit of normal or positive for EBER; CMV copies greater than the upper limit of normal values; HBV or HCV DNA copy number\>the upper limit of normal value, and active syphilis or AIDS and other virus infected persons.
• Subjects who were receiving systemic hormone treatment before screening and who were judged by the investigator to need long-term use of systemic hormone during treatment (except for inhalation or local use).
• Individuals who have participated in other clinical trials within the first 4 weeks of screening.

Sponsors & Collaborators

• Peking University People's Hospital: lead

Study Sites (1)

Peking University People's Hospital

Beijing, China

RECRUITING

Central Study Contacts

Xiaodong Mo, phd

CONTACT

8610-88326002; mxd453@163.com

Na Kuang

CONTACT

86-18630160116; kuangna@senlangbio.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: 3+3 dose escalation design

Study Record Dates

• First Submitted: August 20, 2025
• First Posted: August 27, 2025
• Study Start: August 18, 2025
• Primary Completion (Estimated): July 31, 2026
• Study Completion (Estimated): December 31, 2027
• Last Updated: August 27, 2025

Record last verified: 2025-08

Locations

CN (1)